Healthcare & Medical Services Reservations open Page created Feb 8, 2026

List of Medical Isotope Production Companies

List of companies producing medical radioisotopes including Mo-99, Lu-177, Ac-225, and I-131 for diagnostic imaging and targeted radionuclide therapy. Identify suppliers, production methods, and regulatory approvals to secure your isotope supply chain.

Fields we plan to include

Company Name
Headquarters
Isotopes Produced
Production Method
Regulatory Approvals
Supply Regions
Production Capacity
GMP Certification
Contact Information
Website
Key Therapeutic Areas
Facility Locations

Data Preview

* Free sample rows, unverified and may contain errors. This list isn't for sale yet.
CompanyHeadquartersKey IsotopesProduction Method
NTP RadioisotopesPelindaba, South AfricaMo-99, I-131, Lu-177Reactor-based (SAFARI-1)
SHINE TechnologiesJanesville, WI, USALu-177, Mo-99Fusion-driven neutron activation
Eckert & Ziegler SEBerlin, GermanyGa-68, Y-90, Lu-177, Ac-225Generator & reactor-based
Curium PharmaParis, FranceMo-99, Tc-99m, Lu-177Reactor-based (NRG Petten)
NorthStar Medical RadioisotopesBeloit, WI, USAMo-99, Ac-225Electron accelerator (non-uranium)

Estimated ~85 entries. If people reserve it, we'll try to compile it (we can't compile every list).

* No charge now. Purchase is optional.

The Medical Isotope Production Landscape

The global medical isotope production market—valued at approximately $4.35 billion in 2024 and projected to reach $9.69 billion by 2034—is undergoing a fundamental transformation. The legacy supply chain, historically dependent on a handful of aging research reactors, is being reshaped by new production technologies and a surge in demand driven by theranostics.

Supply Chain Concentration and Risk

For decades, roughly 95% of the world's Mo-99 supply came from just four organizations: Nordion (Canada), Mallinckrodt (Netherlands), IRE (Belgium), and NTP Radioisotopes (South Africa). All relied on government-funded research reactors, several of which have exceeded their original design life. This concentration has led to multiple supply crises—most notably in 2009-2010 when simultaneous reactor shutdowns caused global Tc-99m shortages.

The Shift to New Production Methods

Multiple companies are now deploying alternative production technologies to reduce dependence on aging reactors:

Accelerator-based production
NorthStar Medical Radioisotopes uses electron beam technology on Mo-100 targets, eliminating the need for uranium altogether. Nusano operates a cyclotron-based facility in Utah producing 25+ isotopes.
Fusion-driven systems
SHINE Technologies' proprietary fusion neutron source in Janesville, Wisconsin, is designed to produce both Mo-99 and Lu-177 without a nuclear reactor.
Power reactor harvesting
Laurentis Energy Partners and BWXT Medical are producing Mo-99 from Ontario Power Generation's Darlington station—the first large-scale commercial power reactor used for isotope production.

Therapeutic Isotopes: The Growth Frontier

The explosive growth of radioligand therapy (RLT) has created intense demand for therapeutic isotopes, particularly:

IsotopeApplicationKey Producers
Lu-177Prostate cancer (PSMA), neuroendocrine tumorsSHINE, Curium, NRG PALLAS, ITM
Ac-225Targeted alpha therapy (emerging)Eckert & Ziegler, NorthStar, ORNL
I-131Thyroid cancer, hyperthyroidismNTP, Curium, Jubilant Radiopharma
Y-90Liver cancer (radioembolization)Eckert & Ziegler, Boston Scientific

Novartis's Pluvicto (Lu-177-PSMA-617) approval in 2022 was a watershed moment—demonstrating blockbuster potential for radiopharmaceuticals and triggering a race to secure Lu-177 supply.

Frequently Asked Questions

Q.Where does the data come from?

The lists would be compiled from public sources such as official registries, industry association rosters and company websites. The sample rows on each page come from web searches and are unverified. Organization info only — no personal contact details.

Q.Can I buy the list now?

Not yet. Sample rows are free. We try to compile lists that people reserve (we can't compile every list). If we do, we'll email everyone who reserved it a purchase link (buying is optional). If we don't, nothing happens and you're never charged.

Q.What does it cost?

Sample rows are free. A list is $49, paid only if we compile it and you decide to buy. There is no free trial or subscription.

Q.What format is it delivered in?

CSV (opens in Excel or Google Sheets). There is no API.